{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:25:55Z","timestamp":1787307955337,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,21]]},"DOI":"10.7759\/cureus.114909","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T09:47:01Z","timestamp":1787305621000},"source":"Crossref","is-referenced-by-count":0,"title":["Multimodal Pharmacologic Strategies for Chronic Cancer Pain: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Savannah Q","family":"Thirza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Squire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashique","family":"Ahamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2015.12.340","article-title":"Update on prevalence of pain in patients with cancer: systematic review and meta-analysis","volume":"51","author":"van den Beuken-van Everdingen MH","year":"2016","unstructured":"van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manage. 2016, 51:1070-90.e9. 10.1016\/j.jpainsymman.2015.12.340","journal-title":"J Pain Symptom Manage"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy152","article-title":"Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines","volume":"29","author":"Fallon M","year":"2018","unstructured":"Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, Ripamonti CI. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018, 29:iv166-91. 10.1093\/annonc\/mdy152","journal-title":"Ann Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0032","article-title":"Adult cancer pain, version 2.2025, NCCN Clinical Practice Guidelines in Oncology","volume":"23","author":"Swarm RA","year":"2025","unstructured":"Swarm RA, Youngwerth JM, Agne JL, et al.. Adult cancer pain, version 2.2025, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2025, 23:10.6004\/jnccn.2025.0032","journal-title":"J Natl Compr Canc Netw"},{"key":"ref4","unstructured":"Macmillan Cancer Support. Cancer statistics in the UK. (2026). https:\/\/www.macmillan.org.uk\/about-us\/what-we-do\/research\/cancer-statistics-fact-sheet."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2013.0119","article-title":"Adult cancer pain","volume":"11","author":"Swarm RA","year":"2013","unstructured":"Swarm RA, Abernethy AP, Anghelescu DL, et al.. Adult cancer pain. J Natl Compr Canc Netw. 2013, 11:992-1022. 10.6004\/jnccn.2013.0119","journal-title":"J Natl Compr Canc Netw"},{"key":"ref6","article-title":"WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents. World Health Organization, Geneva; 2018."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.08.083","article-title":"An international, open-label, randomised trial comparing a two-step approach versus the standard three-step approach of the WHO analgesic ladder in patients with cancer","volume":"33","author":"Fallon M","year":"2022","unstructured":"Fallon M, Dierberger K, Leng M, et al.. An international, open-label, randomised trial comparing a two-step approach versus the standard three-step approach of the WHO analgesic ladder in patients with cancer. Ann Oncol. 2022, 33:1296-303. 10.1016\/j.annonc.2022.08.083","journal-title":"Ann Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1049909111413256","article-title":"Adjuvant analgesics in cancer pain: a review","volume":"29","author":"Mitra R","year":"2012","unstructured":"Mitra R, Jones S. Adjuvant analgesics in cancer pain: a review. Am J Hosp Palliat Care. 2012, 29:70-9. 10.1177\/1049909111413256","journal-title":"Am J Hosp Palliat Care"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2019.04.004","article-title":"Pharmacologic management of cancer pain","volume":"35","author":"Howard A","year":"2019","unstructured":"Howard A, Brant JM. Pharmacologic management of cancer pain. Semin Oncol Nurs. 2019, 35:235-40. 10.1016\/j.soncn.2019.04.004","journal-title":"Semin Oncol Nurs"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-024-01248-7","article-title":"Neuropathic pain in cancer: what are the current guidelines?","volume":"25","author":"Mulvey MR","year":"2024","unstructured":"Mulvey MR, Paley CA, Schuberth A, King N, Page A, Neoh K. Neuropathic pain in cancer: what are the current guidelines?. Curr Treat Options Oncol. 2024, 25:1193-202. 10.1007\/s11864-024-01248-7","journal-title":"Curr Treat Options Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/papr.12459","article-title":"Pharmacological treatment of pain in cancer patients: the role of adjuvant analgesics, a systematic review","volume":"17","author":"van den Beuken-van Everdingen MH","year":"2017","unstructured":"van den Beuken-van Everdingen MH, de Graeff A, Jongen JL, Dijkstra D, Mostovaya I, Vissers KC. Pharmacological treatment of pain in cancer patients: the role of adjuvant analgesics, a systematic review. Pain Pract. 2017, 17:409-19. 10.1111\/papr.12459","journal-title":"Pain Pract"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000000995","article-title":"Nonopioid drug combinations for cancer pain: a systematic review","volume":"7","author":"Sohi G","year":"2022","unstructured":"Sohi G, Lao N, Caraceni A, Moulin DE, Zimmermann C, Herx L, Gilron I. Nonopioid drug combinations for cancer pain: a systematic review. Pain Rep. 2022, 7:e995. 10.1097\/PR9.0000000000000995","journal-title":"Pain Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness LA","year":"2021","unstructured":"McGuinness LA, Higgins JP. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021, 12:55-61. 10.1002\/jrsm.1411","journal-title":"Res Synth Methods"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2019.06.020","article-title":"Additive duloxetine for cancer-related neuropathic pain nonresponsive or intolerant to opioid-pregabalin therapy: a randomized controlled trial (JORTC-PAL08)","volume":"58","author":"Matsuoka H","year":"2019","unstructured":"Matsuoka H, Iwase S, Miyaji T, et al.. Additive duloxetine for cancer-related neuropathic pain nonresponsive or intolerant to opioid-pregabalin therapy: a randomized controlled trial (JORTC-PAL08). J Pain Symptom Manage. 2019, 58:645-53. 10.1016\/j.jpainsymman.2019.06.020","journal-title":"J Pain Symptom Manage"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00540-010-0913-6","article-title":"Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine","volume":"24","author":"Arai YC","year":"2010","unstructured":"Arai YC, Matsubara T, Shimo K, et al.. Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. J Anesth. 2010, 24:407-10. 10.1007\/s00540-010-0913-6","journal-title":"J Anesth"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.115003","article-title":"A comparative study of efficacy and safety of gabapentin versus amitriptyline as coanalgesics in patients receiving opioid analgesics for neuropathic pain in malignancy","volume":"45","author":"Banerjee M","year":"2013","unstructured":"Banerjee M, Pal S, Bhattacharya B, et al.. A comparative study of efficacy and safety of gabapentin versus amitriptyline as coanalgesics in patients receiving opioid analgesics for neuropathic pain in malignancy. Indian J Pharmacol. 2013, 45:334-8. 10.4103\/0253-7613.115003","journal-title":"Indian J Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005144","article-title":"The research on long-term clinical effects and patients' satisfaction of gabapentin combined with oxycontin in treatment of severe cancer pain","volume":"95","author":"Chen DL","year":"2016","unstructured":"Chen DL, Li YH, Wang ZJ, Zhu YK. The research on long-term clinical effects and patients' satisfaction of gabapentin combined with oxycontin in treatment of severe cancer pain. Medicine (Baltimore). 2016, 95:e5144. 10.1097\/MD.0000000000005144","journal-title":"Medicine (Baltimore)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-013-0009-8","article-title":"Randomized study of pregabalin in patients with cancer-induced bone pain","volume":"2","author":"Sj\u00f6lund KF","year":"2013","unstructured":"Sj\u00f6lund KF, Yang R, Lee KH, Resnick M. Randomized study of pregabalin in patients with cancer-induced bone pain. Pain Ther. 2013, 2:37-48. 10.1007\/s40122-013-0009-8","journal-title":"Pain Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12311","article-title":"Efficacy and safety of pregabalin in patients with neuropathic cancer pain undergoing morphine therapy","volume":"13","author":"Dou Z","year":"2017","unstructured":"Dou Z, Jiang Z, Zhong J. Efficacy and safety of pregabalin in patients with neuropathic cancer pain undergoing morphine therapy. Asia Pac J Clin Oncol. 2017, 13:e57-64. 10.1111\/ajco.12311","journal-title":"Asia Pac J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059981","article-title":"Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients","volume":"8","author":"Garassino MC","year":"2013","unstructured":"Garassino MC, Piva S, La Verde N, et al.. Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients. PLoS One. 2013, 8:e59981. 10.1371\/journal.pone.0059981","journal-title":"PLoS One"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2012.01.003","article-title":"Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial","volume":"13","author":"Portenoy RK","year":"2012","unstructured":"Portenoy RK, Ganae-Motan ED, Allende S, et al.. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012, 13:438-49. 10.1016\/j.jpain.2012.01.003","journal-title":"J Pain"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2017.09.001","article-title":"Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain","volume":"55","author":"Lichtman AH","year":"2018","unstructured":"Lichtman AH, Lux EA, McQuade R, et al.. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. J Pain Symptom Manage. 2018, 55:179-88.e1. 10.1016\/j.jpainsymman.2017.09.001","journal-title":"J Pain Symptom Manage"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.23455.1","article-title":"Analgesic efficacy of nefopam for cancer pain: a randomized controlled study","volume":"9","author":"Pasutharnchat K","year":"2020","unstructured":"Pasutharnchat K, Wichachai W, Buachai R. Analgesic efficacy of nefopam for cancer pain: a randomized controlled study. F1000Res. 2020, 9:378. 10.12688\/f1000research.23455.1","journal-title":"F1000Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.8356","article-title":"Nonopioid drugs in the treatment of cancer pain","volume":"32","author":"Vardy J","year":"2014","unstructured":"Vardy J, Agar M. Nonopioid drugs in the treatment of cancer pain. J Clin Oncol. 2014, 32:1677-90. 10.1200\/JCO.2013.52.8356","journal-title":"J Clin Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030591","article-title":"Update on prevalence of pain in patients with cancer 2022: a systematic literature review and meta-analysis","volume":"15","author":"Snijders RA","year":"2023","unstructured":"Snijders RA, Brom L, Theunissen M, van den Beuken-van Everdingen MH. Update on prevalence of pain in patients with cancer 2022: a systematic literature review and meta-analysis. Cancers (Basel). 2023, 15:10.3390\/cancers15030591","journal-title":"Cancers (Basel)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2021.09.011","article-title":"Pain prevalence during cancer treatment: a systematic review and meta-analysis","volume":"63","author":"Evenepoel M","year":"2022","unstructured":"Evenepoel M, Haenen V, De Baerdemaecker T, et al.. Pain prevalence during cancer treatment: a systematic review and meta-analysis. J Pain Symptom Manage. 2022, 63:317-35. 10.1016\/j.jpainsymman.2021.09.011","journal-title":"J Pain Symptom Manage"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20112","article-title":"The management of cancer pain","volume":"61","author":"Paice JA","year":"2011","unstructured":"Paice JA, Ferrell B. The management of cancer pain. CA Cancer J Clin. 2011, 61:157-82. 10.3322\/caac.20112","journal-title":"CA Cancer J Clin"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/papr.13098","article-title":"Living systematic review to assess the analgesic undertreatment in cancer patients","volume":"22","author":"Roberto A","year":"2022","unstructured":"Roberto A, Greco MT, Uggeri S, et al.. Living systematic review to assess the analgesic undertreatment in cancer patients. Pain Pract. 2022, 22:487-96. 10.1111\/papr.13098","journal-title":"Pain Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/521722-multimodal-pharmacologic-strategies-for-chronic-cancer-pain-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T09:47:02Z","timestamp":1787305622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/521722-multimodal-pharmacologic-strategies-for-chronic-cancer-pain-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.114909","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,21]]}}}